ArticleEnvironment international2026
Prenatal exposure to acrylamide and metabolic health at 20 years of age A biomarker-based Danish cohort study.
Article in Environment international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult obesity and metabolic health may be influenced by prenatal exposure to acrylamide (AA). AA forms in carbohydrate-containing foods and beverages during high-temperature processing. AA disrupts metabolic homeostasis and induces adiposity in mice offspring following gestational exposure. In humans, AA has been associated with intrauterine growth restriction and childhood overweight. It is unknown if prenatal exposure to AA influences metabolic health in young adults. We examined the associations between prenatal exposure to AA and metabolic health in singletons born in 1988-1989, Denmark. Hemoglobin adducts from AA (HbAA) and glycidamide were measured in maternal blood collected at 30 weeks' gestation together with information on maternal dietary and smoking habits (n = 638). At 20 years of age, offspring waist circumference, weight, height, blood pressure, blood glucose, insulin, leptin, adiponectin and lipid levels were measured at a clinical follow-up. Median HbAA concentration was 85 (interquartile range 63-136) pmol/g Hb. For most outcomes examined, there was no evidence of an association with prenatal exposure to AA. However, higher HbAA levels were associated with a minor increase in the offspring waist circumference of 0.06 cm (95 % confidence interval (CI): -0.07, 0.20) and low-density lipoprotein (LDL) cholesterol concentrations of 0.01 mmol/L (95 % CI: <0.01, 0.03) per 10 pmol/g Hb increments in HbAA. Furthermore, we observed that HbAA levels were associated with increased risk of metabolic syndrome in offspring of non-smokers. We found no overall compelling evidence that prenatal exposure to AA was associated with metabolic health of young adults, but the observations that higher prenatal exposure to AA were associated with higher waist circumference and LDL cholesterol levels in young adults warrants replication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.